No Data
Hualan Vaccine: Report for the third quarter of 2024
Hualan Vaccine (301207.SZ) released its performance for the first three quarters, with a net income of 0.267 billion yuan, a decrease of 57.54%.
Hualan Vaccine (301207.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters at 9...
Hualan Vaccine (301207.SZ): Net income in the first three quarters was 0.267 billion yuan, a year-on-year decrease of 57.54%.
Galenghui October 29th | Hualan Vaccine (301207.SZ) announced the third quarter report of 2024, with the company's revenue reaching 0.957 billion yuan in the first three quarters, a year-on-year decrease of 44.28%; the net income attributable to the company's shareholders was 0.267 billion yuan, a year-on-year decrease of 57.54%; the net income attributable to the company's shareholders excluding non-recurring gains and losses was 0.196 billion yuan, a year-on-year decrease of 64.65%; the basic earnings per share was 0.4463 yuan.
Hualan Vaccine (301207.SZ): Currently, there is no cooperation with foreign giants companies.
On September 20th, Gelonghui announced that Hualan Vaccine (301207.SZ) has consistently adhered to independent research and development, as well as the combination of industry, academia, and research, and has collaborated with domestic high-level universities, research institutes, and other institutions to carry out a series of cooperative research and development work. Currently, there is no collaboration with foreign giants.
HL VACCINE (301207.SZ): Among the vaccines currently in the registration process, there is still no vaccine with antibodies against monkeypox.
On September 20th, Geelong reported that Hualan Vaccine (301207.SZ) stated on the investor interaction platform that among the vaccines under registration procedure, there is currently no vaccine with antibodies against smallpox. The company will continue to focus on cutting-edge categories of vaccines and steadily promote the research and development of products under development.
Hualan Vaccine (301207) Interim Report Review: Performance under pressure, waiting for the sales of flu vaccines to pick up.
Investment Highlights: The company, founded in 2005, went public on the Shenzhen GEM in 2022. It is a high-tech enterprise specialized in the research, production, and sales of human vaccines. Currently, the company has obtained drug registration certificates for its vaccines.
No Data
